Investigators described the toxicity and preliminary activity of rezatapopt in TP53 Y220C–mutated solid tumors. The agent is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, stabilizing p53 in its wild-type conformation and restoring its functionality.
|
ADVERTISEMENT
|
“With tens of millions of people globally experiencing long-term pulmonary [COVID-19] sequelae, these findings carry significant implications for clinical care. Individuals recovering from severe viral pneumonia, particularly those with smoking history, may benefit from enhanced lung cancer surveillance, and preventing severe infection through vaccination may confer indirect cancer protection benefits.”
Significant differences were found in advanced-stage diagnoses of breast cancer in rural populations according to geographic location in the United States, which were further influenced by demographic factors of race and insurance status, according to findings from an analysis of the National Cancer Database.
|
There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richardson, PhD, postdoctoral fellow at the Center for Science of Science and Innovation, Kellogg School of Management at Northwestern University, and his colleagues found that large-scale, systematic fraud is happening on an industrial-sized level; the number of fraudulent scientific papers appears to be doubling every 1.5 years, faster than the increase in scientific papers overall, which is doubling every 15 years.
